NUVB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
45.0M
+41.9%
31.7M
-61.9%
83.2M
+98.8%
41.9M
+219.1%
13.1M
Cost of Revenue
9.8M
+14.6%
8.6M
+52.4%
5.6M
+1227.7%
423.0K
-86.0%
3.0M
Gross Profit
35.1M
+51.9%
23.1M
-70.2%
77.6M
+87.3%
41.4M
+310.1%
10.1M
Operating Expenses
77.3M
+4.3%
74.2M
+0.6%
73.7M
-1.6%
74.9M
+12.6%
66.5M
R&D
32.7M
+6.6%
30.7M
-12.5%
35.0M
+2.2%
34.3M
+18.9%
28.8M
SG&A
44.7M
+2.7%
43.5M
+12.5%
38.7M
-4.8%
40.6M
+7.8%
37.7M
Operating Income
-42210000
+17.3%
-51036000
-1415.0%
3.9M
+111.6%
-33481000
+40.7%
-56434000
EBITDA
-41632000
+17.6%
-50500000
-1243.3%
4.4M
+113.4%
-32942000
+41.1%
-55900000
Net Income
-41899000
+33.3%
-62840000
-1264.4%
5.4M
+114.7%
-36592000
+34.4%
-55792000
EPS (Basic)
$-0.12
+33.3%
$-0.18
-1000.0%
$0.02
+118.2%
$-0.11
+31.3%
$-0.16
EPS (Diluted)
$-0.12
+33.3%
$-0.18
-1900.0%
$0.01
+109.1%
$-0.11
+31.3%
$-0.16
Shares (Diluted)
351.9M
+0.9%
348.8M
-7.6%
377.5M
+9.6%
344.4M
+0.6%
342.4M
Nuvation Bio (NUVB) — Financials